Sera Prognostics

Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. It focuses on developing blood tests to predict the risks of preterm birth, preeclampsia and other pregnancy complications. The company was founded by Steven W. Graves, Dennis Farrar and M. Sean Esplin in 2008 and is headquartered in Salt Lake City, UT.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sera Prognostics reports revenue growth and innovation drive amidst challenges

Sera Prognostics demonstrated strong financial performance with revenue growth and reduced net loss in Q4 2022.
The company's focus on innovation, new data, and upcoming studies positions it well for future growth and market success.
Challenges in revenue expectations and payer dynamics require strategic navigation, but opportunities from studies and technology advancements are promising.

Sera Prognostics reports robust Q1 performance amidst revenue challenges

Sera Prognostics demonstrated strong performance in Q1 2023 with notable revenue growth and positive trial outcomes, showcasing its research capabilities and commitment to innovation.
While facing challenges in revenue projections and financial losses, the company's strategic focus on cost efficiency and strong cash reserves provide a foundation for future growth.
Opportunities lie in upcoming study analyses, continued research efforts, and potential partnerships, positioning Sera Prognostics for sustainable development and market expansion.

Sera Prognostics reports stable Q2 revenue, eyes growth opportunities

Sera Prognostics demonstrated stable financial performance in Q2 2023, with a focus on revenue growth and cost management.
The company's PreTRM test showed promising results in reducing neonatal length of stay, enhancing its market position.
While facing challenges in commercialization and global scaling, Sera has opportunities to expand revenue streams and strengthen partnerships.

SERA reports Q3 revenue growth, focuses on expense management

SERA's financials show revenue growth potential with a focus on expense management
Balancing product development and study outcomes crucial for future success
Strategic steps taken to ensure operational sustainability and revenue growth

Sera Prognostics reports positive study outcomes amidst financial challenges

Sera Prognostics demonstrated positive study outcomes with potential for improved neonatal health, despite a net loss in Q4 2023.
Strategic focus on managing expenses, leveraging study results, and achieving key milestones for future revenue growth.
Opportunities lie in lower cash expenses for 2024, revenue growth initiatives, and the launch of a blood sample self-collection device.
Challenges include balancing financial performance, cash management, and addressing analyst inquiries.

Sera Prognostics reports improved Q1 financials and eyes global expansion

Sera Prognostics made strides in financial performance and operational efficiency in Q1 2024.
The company's focus on expanding test adoption and improving margins shows promise for growth.
Despite challenges like regulatory impacts, Sera Prognostics is poised for strategic investments and market expansion.

Sera Prognostics reports Q2 revenue decline, focuses on growth strategies

Sera Prognostics navigated challenges with decreased revenue and a net loss in Q2 2024, emphasizing cost management and efficiency.
The company's strengths lie in strategic progress, enhanced market visibility, and new market opportunities with the PreTRM Test approval.
Opportunities exist in leveraging study results for product adoption, expanding market reach through awareness initiatives, and utilizing financial flexibility for growth.

Sera Prognostics focuses on combating premature births, strengthens revenue growth

Sera Prognostics is actively working to combat premature birth risks in the U.S.
Despite financial challenges, the company maintains a solid cash position for growth
Strategic initiatives aim to increase revenue and awareness for sustainable progress

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sera Prognostics, Inc. (NASDAQ:SERA ) Q1 2022 Earnings Conference Call May 10, 2022 5:00 PM ET Company Participants Peter DeNardo - Investor Relations Greg Critchfield - Chairman, President and Chief Executive Officer Jay Moyes - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Dustin Scaringe - Blair Anita Dushyanth - Berenberg Operator Good afternoon and welcome to the Sera Prognostics' Conference Call to review First Quarter Fiscal Year 2022 Results. At this time, all participants are in a listen-only mode.

Sera Prognostics, Inc. (SERA) CEO Greg Critchfield on Q1 2022 Results - Earnings Call Transcript

SALT LAKE CITY , May 10, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter ended March 31, 2022. Recent Highlights: Simplified and streamlined the PreTRM® test ordering process, resulting in increased numbers of orders and ordering physicians.

SERA PROGNOSTICS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS

Project focused on reducing maternal and neonatal mortality and morbidity by mitigating risks associated with unanticipated preterm birth SALT LAKE CITY , May 5, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, and the Newborn Foundation today announced the launch of the Every Mother, Every Baby Project. The Every Mother, Every Baby Project, developed by the Newborn Foundation in partnership with Sera, is designed to educate clinical practitioners, policymakers, and public health stakeholders about the critical role that validated biomarker-based preterm risk assessment tests like Sera's PreTRM® test can play in improving neonatal and maternal health outcomes.

SERA PROGNOSTICS AND NEWBORN FOUNDATION PARTNER TO REDUCE RISKS ASSOCIATED WITH PRETERM BIRTH AND IMPROVE HEALTH EQUITY THROUGH THE "EVERY MOTHER, EVERY BABY" PROJECT

SALT LAKE CITY , May 2, 2022 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2022 financial results on Tuesday, May 10, 2022, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.

Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2022 Financial Results on May 10

- Accomplished business and health services leader joins Sera in its quest to improve pregnancy outcomes of mothers and babies - SALT LAKE CITY , April 12, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Dr. Jane F. Barlow has joined the Sera Board of Directors.

SERA PROGNOSTICS ANNOUNCES THE APPOINTMENT OF DR. JANE F. BARLOW TO THE SERA PROGNOSTICS BOARD

Sera Prognostics, Inc. (SERA) CEO Gregory Critchfield on Q4 2021 Earnings Call Transcript

SALT LAKE CITY , March 29, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year 2021 ended December 31, 2021. Recent Highlights: Our sales team is focusing geographically in high population density areas, where Anthem and other payers are concentrated.

SERA PROGNOSTICS REPORTS FOURTH QUARTER 2021 FINANCIAL RESULTS

SALT LAKE CITY , March 18, 2022 /PRNewswire/ --  Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today presented data demonstrating the effective prediction of preeclampsia using protein biomarkers and clinical factors. The presentation titled "Comparison of Protein Biomarkers to Clinical Factors for Preeclampsia in Two Cohorts" was given by lead author Julja Burchard et al this morning at the 69th Annual Meeting of the Society for Reproductive Investigation (SRI) in Denver, Colorado, during Late Breaking Session LB-002 from 9:00-10:30 AM.

Sera Prognostics Presents Data Demonstrating Prediction of Preeclampsia Utilizing Protein Biomarker and Clinical Factors at SRI Annual Meeting

SALT LAKE CITY , March 18, 2022 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth quarter and full year 2021 financial results on Tuesday, March 29, 2022, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.

Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2021 Financial Results on March 29

SALT LAKE CITY, Feb. 17, 2022 /PRNewswire/ --  Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that its presentation at the virtual Citi 2022 Healthcare Conference: Services, MedTech, Life Science Tools & HCIT, to be held February 23-24, 2022, has been rescheduled. Gregory C.

SERA PROGNOSTICS PRESENTATION RESCHEDULED FOR CITI 2022 HEALTHCARE CONFERENCE

SALT LAKE CITY, Feb. 7, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the upcoming virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference and the virtual Citi 2022 Healthcare Conference: Services, MedTech, Life Science Tools & HCIT. Gregory C.

SERA PROGNOSTICS TO PRESENT AT UPCOMING FEBRUARY INVESTOR CONFERENCES

SALT LAKE CITY, Feb. 1, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the execution of an agreement with MultiPlan, for participation in its PHCS and MultiPlan Networks. The agreement will help expand access to the PreTRM® Test, the company's proprietary proteomic blood test for measuring a woman's risk of spontaneous preterm birth, to allow more timely intervention to the members accessing MultiPlan's services through its more than 700 healthcare payers and the 1.2 million healthcare providers participating in MultiPlan's provider networks.

SERA PROGNOSTICS ANNOUNCES NEW AGREEMENT WITH MULTIPLAN, EXPANDING PATIENT ACCESS TO THE PRETRM® TEST

SALT LAKE CITY, Dec. 15, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI). The addition is based on the annual reconstitution of the index announced by Nasdaq and will become effective prior to the U.S. stock market open on Monday, December 20, 2021.

SERA PROGNOSTICS ADDED TO NASDAQ BIOTECHNOLOGY INDEX

SALT LAKE CITY, Dec 2, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the Centers for Medicare & Medicaid Services (CMS) has set a Medicare payment rate for the existing unique Proprietary Laboratory Analysis (PLA) code, 0247U, for the PreTRM® test, the company's proprietary proteomic blood test for measuring a woman's risk of spontaneous preterm birth to allow more timely intervention. This payment rate for the 0247U code is scheduled to go into effect on January 1, 2022 and is expected to apply for CY 2022, at a rate of $750.00.

Sera Prognostics Announces Pricing For PreTRM® Test, The Only Broadly Validated Blood Test To Assess Risk Of Preterm Birth

SALT LAKE CITY, Dec. 1, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the publication of a study funded by the Bill & Melinda Gates Foundation and in collaboration with AMANHI (Alliance for Maternal and Newborn Health Improvement), a multinational effort to improve health for pregnant and postpartum women and their babies in sub-Saharan Africa and South Asia. The newly published article presents the performance of the IBP4/SHBG biomarker pair in predicting spontaneous preterm birth (sPTB) in low and middle income geographies, with prespecified adjustment for demographic differences between the populations.

Sera Prognostics Announces Publication Of Data Confirming The Performance Of The IBP4/SHBG Biomarkers In Diverse Non-U.S. Populations

SALT LAKE CITY, Nov. 30, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Sandra A. J. Lawrence has joined the Sera Board of Directors.

Sera Prognostics Announces The Appointment Of Sandra A.J. Lawrence To The Sera Prognostics Board

SALT LAKE CITY, Nov. 9, 2021 /PRNewswire/ --  Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter ended September 30, 2021. Recent Highlights: Made key hires in scaling the company's salesforce, now totaling 26 representatives, with Sera Prognostics seeing early payer revenues and positive physician office reception to the company's PreTRM® test.

Sera Prognostics Reports Third Quarter 2021 Financial Results

SALT LAKE CITY, Nov. 8, 2021 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Zhenya Lindgardt has joined the Sera Board of Directors. "We are thrilled to have Zhenya Lindgardt bring her vast and highly relevant experience to our board to improve the well-being of mothers and babies," said Gregory C.

Sera Prognostics Announces The Appointment Of Zhenya Lindgardt To The Board

SALT LAKE CITY, Nov. 4, 2021 /PRNewswire/ --  Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Woodrow Myers, M.D., M.B.A., joins Sera as an advisor focusing on public and political affairs.

Sera Prognostics Appoints Woodrow Myers, MD, MBA As Advisor Of Public And Political Affairs

SALT LAKE CITY, Nov. 3, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the publication of a rigorous validation of a clinical decision point at spontaneous preterm birth (sPTB) risk of 15%, as determined by the Company's PreTRM® test. In the Proteomic Assessment of Preterm Risk (PAPR) study, it was demonstrated that patients at or above 15% risk, or twice the intended use population risk, had significantly higher risk of sPTB.

Sera Prognostics Announces Publication of the Clinical Validation of PreTRM® Threshold for Clinical Action

SALT LAKE CITY, Nov. 2, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced a partnership with PreemieWorld, GLO Preemies, and the Alliance for Black NICU Families, leading organizations all geared to empowering and supporting families impacted by preterm birth. "We are committed to help address the healthcare disparities that disproportionately affect underserved communities, particularly among African Americans," said Gregory C.

Sera Prognostics Announces Collaboration To Help Underserved Communities Make Informed Decisions About Prenatal Health

SALT LAKE CITY, Oct. 27, 2021 /PRNewswire/ -- Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third quarter 2021 financial results on Tuesday, November 9, 2021, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.

Sera Prognostics Announces Conference Call and Webcast of Third Quarter 2021 Financial Results on November 9

Brings extensive data science, bioinformatics and proteomics experience to foster further product innovation and informed healthcare insights into pregnancy

Sera Prognostics Appoints Dr. Paul Kearney as Chief Data Officer

SALT LAKE CITY, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that according to a preliminary list of initial public offering (IPO) additions to the Russell indexes, the company will be added to the Russell 2000 Index effective Sept. 20, 2021.

Sera Prognostics to be Added to Russell 2000 Index

SALT LAKE CITY, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Dr. Michael R. Foley has been appointed to the position of Chief Medical Officer beginning in January 2022. Dr. Foley will lead all medical activities for Sera as the company executes its vision to be the Pregnancy Company™. He joins a group of talented clinical operations and medical professionals who support Sera's collaborations with research teams across the globe.

News for Sera Prognostics Stock (SERA)